Hepatocellular carcinoma (HCC) is one of those Step 1 topics that keeps showing up because it’s the final common pathway of chronic liver injury. If you can connect the risk factors (HBV, HCV, cirrhosis, aflatoxin, hemochromatosis) to the underlying pathophysiology and the classic test clues (AFP, weight loss, RUQ pain, paraneoplastic syndromes), you’ll pick up a lot of “free points” on GI and oncology-style questions.
Where HCC Fits in GI + Onc (Big Picture)
HCC = primary malignant tumor of hepatocytes, most often arising in the setting of chronic inflammation → regeneration → dysplasia → cancer.
Step framing: HCC is classically tested as a consequence of:
- Cirrhosis (any cause, but especially viral hepatitis and alcohol-related disease)
- Chronic viral hepatitis (HBV and HCV)
- Dietary toxin exposure (aflatoxin)
First Aid cross-reference: GI — Liver tumors; Hepatitis; Cirrhosis; Tumor markers (AFP)
Definition (One-liner for NBME style)
Hepatocellular carcinoma is a primary liver cancer derived from hepatocytes, strongly associated with chronic liver disease and often marked by elevated alpha-fetoprotein (AFP).
Pathophysiology (How You Get from Injury to Cancer)
Core mechanism: chronic injury → regeneration → mutations
Repeated cycles of hepatocyte death and regeneration create a pro-oncogenic environment:
- Inflammation → cytokines + oxidative stress
- Regenerative nodules → increased DNA replication errors
- Fibrosis/cirrhosis → altered microenvironment promoting dysplasia
Viral hepatitis connections (high-yield differentiators)
| Virus | How it increases HCC risk | Key Step takeaway |
|---|---|---|
| HBV | Can integrate into host DNA (direct oncogenic potential) + chronic inflammation | HCC can occur with or without cirrhosis in HBV |
| HCV | Chronic inflammation (no integration) → usually via cirrhosis | HCC risk is strongly tied to cirrhosis |
First Aid cross-reference: HBV integration is a classic “why HBV causes HCC” line.
Aflatoxin (classic toxin association)
- Produced by Aspergillus flavus (mold on stored grains/peanuts)
- Causes p53 tumor suppressor mutation
- Synergizes with chronic HBV to elevate HCC risk further
First Aid cross-reference: Aflatoxin → p53 mutation → HCC is a high-yield toxin-cancer pairing.
Other high-yield risk factors (often show up as vignettes)
- Cirrhosis (alcohol, NAFLD/NASH, chronic viral hepatitis)
- Hemochromatosis (iron overload → oxidative damage)
- Primary biliary cholangitis / Primary sclerosing cholangitis (cirrhosis over time)
- Alpha-1 antitrypsin deficiency
- Diabetes/obesity via NAFLD/NASH progression
Clinical Presentation (What You See on Test Day)
Typical symptoms/signs
HCC may be silent early. When symptomatic, think:
- RUQ pain
- Weight loss
- Anorexia
- Hepatomegaly
- Worsening decompensated cirrhosis (new/worse ascites, encephalopathy, variceal bleed)
- Jaundice (variable; can occur late)
Red flags in cirrhosis patients
In a patient with known cirrhosis/hepatitis, clues for HCC include:
- New “rapid deterioration” in liver function
- New mass or enlarging liver
- Rising AFP (especially if trending up)
Paraneoplastic syndromes (Step favorite)
HCC can produce hormone-like substances leading to:
- Hypoglycemia (tumor glucose consumption and altered metabolism)
- Erythrocytosis (increased EPO-like activity)
Diagnosis (How NBME Wants You to Confirm It)
Screening (who gets it and how)
High-risk patients (especially cirrhosis or chronic HBV) are typically screened with:
- Ultrasound every 6 months (common guideline-based approach)
- AFP may be used adjunctively, but AFP alone is not a perfect screening test
(On Step 1, they won’t grill guideline intervals as hard as Step 2, but “US + AFP in cirrhosis” is commonly referenced.)
Diagnostic workup: imaging first, not biopsy (often)
Classic Step-style diagnostic flow:
- Ultrasound detects a suspicious lesion
- Multiphasic CT or MRI to characterize lesion
- Hallmark: arterial phase hyperenhancement with venous/delayed washout (because HCC is arterialized)
Why biopsy is not always first-line: risk of bleeding and tumor seeding, and characteristic imaging can be diagnostic.
Tumor marker: AFP (Alpha-fetoprotein)
- AFP is associated with HCC and also yolk sac tumors
- Not all HCC makes AFP, so normal AFP does not exclude HCC
- Rising AFP in a high-risk patient is concerning
First Aid cross-reference: AFP — HCC and yolk sac tumor; also increased in pregnancy/neural tube defects
Gross and Histology (Worth Knowing for Step 1)
- Often arises in a cirrhotic liver with multiple nodules
- Can be multifocal
- Histology may show malignant hepatocytes arranged in trabecular patterns (details vary by source and are less commonly tested than risk factors/AFP)
Treatment (Step 1-Level + Common Step 2 Connections)
Curative-intent options (when localized/appropriate candidate)
- Surgical resection (if sufficient functional liver reserve)
- Liver transplantation (especially for cirrhosis + limited tumor burden)
- Local ablation (radiofrequency/microwave) for small lesions
Locoregional therapies (bridge or palliation)
- TACE: transarterial chemoembolization
- Radioembolization (e.g., Y-90)
Systemic therapy (advanced disease)
Classically tested systemic options include:
- Tyrosine kinase inhibitors (e.g., sorafenib, lenvatinib)
- Immunotherapy (checkpoint inhibitors in appropriate settings; more Step 2/real-world oriented)
Step emphasis: You’re more likely to be asked who is eligible for transplant vs resection than specific drug regimens.
Must-Know Differentials (Quick Comparisons)
HCC vs Cholangiocarcinoma
| Feature | HCC | Cholangiocarcinoma |
|---|---|---|
| Cell of origin | Hepatocytes | Bile duct epithelium |
| Big associations | HBV/HCV, cirrhosis, aflatoxin | PSC, liver flukes (Clonorchis/Opisthorchis) |
| Tumor marker | AFP | CA 19-9 (often), CEA can be elevated |
HCC vs Hepatic hemangioma
- Hemangioma: benign, often incidental, vascular lesion; may show peripheral nodular enhancement
- HCC: malignant, systemic symptoms, AFP association, high-risk liver background
HCC vs Metastatic cancer to liver
- Most liver tumors are metastases (commonly from colon, pancreas, lung, breast)
- Metastases often present as multiple lesions; HCC is more likely with cirrhosis and AFP elevation
High-Yield Associations and “Trigger Phrases” (Memorize These)
Risk factor triggers
- HBV infection → HCC (can be without cirrhosis)
- HCV infection → HCC (usually via cirrhosis)
- Aflatoxin (Aspergillus flavus) → p53 mutation → HCC
- Hemochromatosis → “bronze diabetes” + cirrhosis → HCC
- NAFLD/NASH → cirrhosis → HCC
Vignette triggers
- Chronic hepatitis + weight loss + RUQ pain + hepatomegaly
- Cirrhosis patient with sudden worsening ascites or decline
- Elevated AFP
- Imaging showing arterial enhancement with washout
HY Question Stems (Practice Like NBME)
-
A patient with chronic HBV has a liver mass and elevated AFP. What mutation is associated with toxin exposure that increases risk?
→ p53 (aflatoxin) -
A cirrhotic patient gets surveillance ultrasound showing a lesion with arterial enhancement and venous washout on MRI. Most likely diagnosis?
→ Hepatocellular carcinoma -
Patient with chronic hepatitis deteriorates quickly and develops hypoglycemia. Mechanism?
→ Paraneoplastic effect / increased tumor metabolic demand (HCC association)
First Aid “Anchor” Checklist (Fast Review)
- HCC risk factors: HBV, HCV, cirrhosis, aflatoxin (p53), hemochromatosis
- AFP elevated (but not always)
- HBV can cause HCC without cirrhosis
- Aflatoxin from Aspergillus flavus (grains/peanuts)
- Imaging hallmark: arterial enhancement + venous washout